Nilotinib Pharmascience

Nilotinib, the active ingredient in Nilotinib Pharmascience, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia in adult patients, targeting the BCR‑ABL fusion protein that drives disease progression.

GNH USA supplies Nilotinib Pharmascience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. It operates with a focus on patient safety and regulatory compliance.

Nilotinib is a targeted therapy that inhibits the BCR‑ABL tyrosine kinase pathway in chronic myeloid leukemia.

- Chronic myeloid leukemia (chronic phase): reduces leukemic cell proliferation and improves survival. - Accelerated phase chronic myeloid leukemia: achieves disease control and delays progression. - Blast phase chronic myeloid leukemia: provides cytogenetic response in combination with other agents.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often transient. - Rash: skin erythema or pruritus. - Elevated liver enzymes: increased ALT/AST levels. - Fatigue: general tiredness. - Muscle cramps: involuntary leg or calf cramps.

Serious or Rare Side Effects: - Cardiovascular events: including arterial occlusive disease or myocardial infarction. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Severe hepatic toxicity: marked liver injury or failure. - QT interval prolongation: risk of serious cardiac arrhythmia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Nilotinib, clinicians should consider several safety measures and monitoring requirements.

- Cardiac assessment: evaluate baseline ECG and monitor for QT prolongation. - Hepatic function: check liver enzymes before and during therapy. - Metabolic monitoring: assess blood glucose and lipid levels regularly. - Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors. - Pregnancy and lactation: contraindicated; advise effective contraception for women of childbearing potential. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Nilotinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nilotinib levels and risk serious toxicity. - Proton pump inhibitors (e.g., omeprazole) taken concurrently: reduce nilotinib absorption significantly. - Antacids containing aluminum or magnesium: decrease drug bioavailability.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib exposure, reducing efficacy. - Anticoagulants (e.g., warfarin): may require INR monitoring due to potential interaction. - Statins metabolized by CYP3A4 (e.g., simvastatin): may need dose adjustment to avoid increased statin levels.